Prof. Dr. MURAT AKOVA

Yayın Ağı

Makaleler 159

1. Quantitative Immunoglobulin G and Interferon-Gamma Responses After Different Booster Strategies of CoronaVac and BNT162b2 Vaccines in Turkiye

Ocakli A. I., Ozyar-Kurtcu S. A., Uzun M., KAŞIKCI ÇAVDAR M., Telli-Dizman G., METAN G., et al.

INFECTIOUS DISEASES AND CLINICAL MICROBIOLOGY , cilt.7, sa.2, ss.156-165, 2025 (ESCI, TRDizin) Sürdürülebilir Kalkınma

2. Effectiveness and tolerability of intravenous fosfomycin in treating complicated urinary tract infections caused by Escherichia coli: a prospective cohort study from the FOSFOMIC project

Moreno-Mellado E., ASLAN A. T., AKOVA M., Leon E., Merchante N., Vinuesa D., et al.

CLINICAL MICROBIOLOGY AND INFECTION , sa.5, ss.839-846, 2025 (SCI-Expanded, Scopus)

3. Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL)

Pagano L., Maschmeyer G., Lamoth F., Blennow O., Xhaard A., Spadea M., et al.

LEUKEMIA , 2025 (SCI-Expanded, Scopus)

4. Shortening antibiotic therapy duration for hospital-acquired bloodstream infections in critically ill patients: a causal inference model from the international EUROBACT-2 database

Gajdos L., Buetti N., Tabah A., Ruckly S., AKOVA M., Sjoval F., et al.

INTENSIVE CARE MEDICINE , 2025 (SCI-Expanded, Scopus)

5. Febrile neutropenia management in high-risk neutropenic patients: a narrative review on antibiotic prophylaxis and empirical treatment

BOŞNAK C., AKOVA M.

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY , 2025 (SCI-Expanded)

6. Incorporating ethics into infectious disease clinical practice guidelines

Righi E., Yahav D., Nasim A., AKOVA M., Barac A., Scudeller L., et al.

CLINICAL MICROBIOLOGY AND INFECTION , sa.4, ss.560-567, 2025 (SCI-Expanded, Scopus)

7. Comparison of piperacillin-tazobactam and vancomycin (TZP-VAN) with piperacillin-tazobactam and teicoplanin (TZP-TEI) for the risk of acute kidney injury (CONCOMITANT): A prospective observational, multinational, multi-centre cohort study

Aslan A. T., KARA E., Koksal G., Bilir Y., Saracoglu K. T., ESER F., et al.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS , sa.3, 2025 (SCI-Expanded, Scopus)

8. Infectious diseases ethics: a worldwide survey

Righi E., Mirandola M., Grossi A. A., AKOVA M., Tacconelli E., Fratucello A., et al.

CLINICAL MICROBIOLOGY AND INFECTION , sa.2, ss.282-289, 2025 (SCI-Expanded, Scopus)

9. Prevention and treatment of bacterial infections in patients with haematological cancers and haematopoietic stem cell transplantation: headways and shortcomings

ER A. G., Aslan A. T., Mikulska M., AKOVA M.

CLINICAL MICROBIOLOGY AND INFECTION , sa.1, ss.24-28, 2025 (SCI-Expanded, Scopus)

10. The Heterogeneous Syndrome of Noninfectious Causes of Persistent Fever in Neutropenic Patients With Hematologic Malignancy: Another Opportunity for Stewardship?

Aslan A. T., AKOVA M., Kontoyiannis D. P.

CLINICAL INFECTIOUS DISEASES , cilt.79, ss.1333-1337, 2024 (SCI-Expanded, Scopus)

11. Hospital-acquired bloodstream infections in critically ill cirrhotic patients: a post-hoc analysis of the EUROBACT-2 international cohort study

Wozniak H., Tabah A., Barbier F., Ruckly S., Loiodice A., AKOVA M., et al.

ANNALS OF INTENSIVE CARE , cilt.14, sa.1, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

12. Milestones and Momentum: Celebrating Six Years of Progress in Infectious Diseases and Clinical Microbiology (IDCM)

AKOVA M.

INFECTIOUS DISEASES AND CLINICAL MICROBIOLOGY , cilt.6, sa.4, ss.257, 2024 (ESCI, Scopus, TRDizin)

13. Scientific misconduct in infectious diseases-European Society of Clinical Microbiology and Infectious Diseases survey

Tau N., AKOVA M., Barac A., Nasim A., Righi E., Yahav D.

CLINICAL MICROBIOLOGY AND INFECTION , cilt.30, sa.11, 2024 (SCI-Expanded, Scopus)

14. Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B)

Stemler J., Yeghiazaryan L., Stephan C., Mohn K. G., Carcas-Sansuan A., Rodriguez E. R., et al.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES , cilt.146, 2024 (SCI-Expanded, Scopus)

15. Attributable mortality of candidemia - Results from the ECMM Candida III multinational European Observational Cohort Study

Salmanton-Garcia J., Cornely O. A., Stemler J., Barac A., Steinmann J., Sivakova A., et al.

JOURNAL OF INFECTION , cilt.89, sa.3, 2024 (SCI-Expanded, Scopus)

16. An Institutional Febrile Neutropenia Protocol Improved the Antibacterial Treatment and Encouraged the Development of a Computerized Clinical Decision Support System

TAŞ Z., METAN G., TELLİ DİZMAN G., Yavuz E., DİZDAR Ö., BÜYÜKAŞIK Y., et al.

ANTIBIOTICS-BASEL , cilt.13, sa.9, 2024 (SCI-Expanded, Scopus)

17. Risk factors for bloodstream infections due to carbapenem-resistant Enterobacterales: a nested case-control-control study

Zhou H., Buetti N., Perez-Galera S., Bravo-Ferrer J., Gutierrez-Gutierrez B., Paniagua-Garcia M., et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY , cilt.79, ss.2132-2141, 2024 (SCI-Expanded, Scopus)

18. Effect of therapeutic plasma exchange on antimicrobials in critically ill patients

Balaban U., Kara E., Kaya E. K., Özcebe O. İ., Akova M., Topeli İskit A., et al.

CRITICAL CARE , sa.1, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

19. Beyond conventional dosing: tailoring antimicrobial regimens for cachexia

KILINÇ E. E., BAYRAKTAR ALKAN İ., KARA E., DEMİRKAN S. K., AKOVA M.

EUROPEAN JOURNAL OF HOSPITAL PHARMACY , 2024 (SCI-Expanded, Scopus)

20. Pseudomonas aeruginosa Bloodstream Infections Presenting with Septic Shock in Neutropenic Cancer Patients: Impact of Empirical Antibiotic Therapy

Royo-Cebrecos C., Laporte-Amargos J., Pena M., Ruiz-Camps I., Garcia-Vidal C., Abdala E., et al.

MICROORGANISMS , cilt.12, sa.4, 2024 (SCI-Expanded, Scopus)

21. Invasive Fungal Diseases in Adult Patients in Intensive Care Unit (FUNDICU): 2024 consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAM

Bassetti M., Giacobbe D. R., Agvald-Ohman C., AKOVA M., Alastruey-Izquierdo A., ARIKAN AKDAĞLI S., et al.

Intensive Care Medicine , cilt.50, sa.4, ss.502-515, 2024 (SCI-Expanded, Scopus)

22. Common Problems and Solutions in the Management of Resistant Gram-Negative Bacterial Infections: Expert Opinion on Clinical Practice

Suemer S., Azap o. K. U. R. T., Ayguen G., AKALIN E. H., AKOVA M., KÖKSAL I.

FLORA INFEKSIYON HASTALIKLARI VE KLINIK MIKROBIYOLOJI DERGISI , cilt.29, sa.1, ss.1-24, 2024 (ESCI, TRDizin)

23. Attributable mortality of infections caused by carbapenem-resistant Enterobacterales: results from a prospective, multinational case-control-control matched cohorts study (EURECA)

Paniagua-García M., Bravo-Ferrer J. M., Pérez-Galera S., Kostyanev T., de Kraker M. E. A., Feifel J., et al.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases , cilt.30, sa.2, ss.223-230, 2024 (SCI-Expanded, Scopus)

24. Current practice of screening and antimicrobial prophylaxis to prevent Gram-negative bacterial infection in high-risk haematology patients: results from a pan-European survey

Stemler J., Gavriilaki E., Hlukhareva O., Khanna N., Neofytos D., AKOVA M., et al.

THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE , cilt.11, 2024 (ESCI, Scopus)

25. Recent updates in treating carbapenem-resistant infections in patients with hematological malignancies

Aslan A. T., AKOVA M.

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY , cilt.22, ss.1055-1071, 2024 (SCI-Expanded, Scopus)

26. The role of centre and country factors on process and outcome indicators in critically ill patients with hospital-acquired bloodstream infections

Buetti N., Tabah A., Setti N., Ruckly S., Barbier F., AKOVA M., et al.

Intensive Care Medicine , 2024 (SCI-Expanded, Scopus)

27. Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients

Teh B. W., Mikulska M., Averbuch D., de la Camara R., Hirsch H. H., AKOVA M., et al.

The Lancet Infectious Diseases , cilt.24, sa.1, 2024 (SCI-Expanded, Scopus)

28. "Good" News from IDCM and Thanks to All Who Contributed

AKOVA M.

INFECTIOUS DISEASES AND CLINICAL MICROBIOLOGY , cilt.5, sa.4, ss.266, 2023 (ESCI, TRDizin)

29. The Challenges of Vaccine Trial Participation among Underserved and Hard-to-Reach Communities: An Internal Expert Consultation of the VACCELERATE Consortium

Poulimeneas D., Koniordou M., Kousi D., Merakou C., Kopsidas I., Tsopela G. C., et al.

VACCINES , cilt.11, sa.12, 2023 (SCI-Expanded, Scopus)

30. Human memory T cell dynamics after aluminum-adjuvanted inactivated whole-virion SARS-CoV-2 vaccination

Tavukcuoglu E., Yanik H., Parveen M., Uluturk S., DURUSU TANRIÖVER M., İNKAYA A. Ç., et al.

Scientific Reports , cilt.13, sa.1, 2023 (SCI-Expanded, Scopus)

31. Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1)

Neuhann J. M., Stemler J., Carcas A. J., Frías-Iniesta J., AKOVA M., Bethe U., et al.

Vaccine , cilt.41, sa.48, ss.7166-7175, 2023 (SCI-Expanded, Scopus)

32. Epidemiology and risk factors of 28-day mortality of hospital-acquired bloodstream infection in Turkish intensive care units: a prospective observational cohort study

ASLAN A. T., Tabah A., KÖYLÜ B., Kalem A. K., AKSOY F., Erol Ç., et al.

The Journal of antimicrobial chemotherapy , cilt.78, sa.7, ss.1757-1768, 2023 (SCI-Expanded, Scopus)

33. VACCELERATE Site Network: Real-time definition of clinical study capacity in Europe

Salmanton-García J., Wipfler P., Valle-Simón P., Merakou C., Kopsidas I., Bethe U., et al.

Vaccine , cilt.41, sa.26, ss.3915-3922, 2023 (SCI-Expanded, Scopus)

34. Duration of antibiotic treatment and timing of oral switching for bloodstream infections: a survey on the practices of infectious diseases and intensive care physicians

Isler B., Aslan A. T., BENLİ B. S., Paterson D. L., Daneman N., Fowler R., et al.

International Journal of Antimicrobial Agents , cilt.61, sa.6, 2023 (SCI-Expanded, Scopus)

35. Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study

Hoenigl M., Salmanton-García J., Egger M., Gangneux J., Bicanic T., ARIKAN AKDAĞLI S., et al.

The Lancet Infectious Diseases , cilt.23, sa.6, ss.751-761, 2023 (SCI-Expanded, Scopus)

36. Q Fever Endocarditis-Associated Immune Complex-Mediated Proliferative Glomerulonephritis: Fourth Case from Türkiye Q Ateşi Endokarditi İlişkili İmmün Kompleks Aracılı Proliferatif Glomerülonefrit: Türkiye’den Dördüncü Olgu

Ismayilov R., Acar B. N., KAPAR B., ERDUT A., ÖZDEDE M., Sağlam A., et al.

Mikrobiyoloji bulteni , cilt.57, sa.2, ss.293-300, 2023 (SCI-Expanded, Scopus, TRDizin)

37. Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA)

Pérez-Galera S., Bravo-Ferrer J. M., Paniagua M., Kostyanev T., de Kraker M. E., Feifel J., et al.

eClinicalMedicine , cilt.57, 2023 (SCI-Expanded, Scopus)

38. Risk factors for Gram-negative bacterial infection of cardiovascular implantable electronic devices: multicentre observational study (CarDINe Study)

Pascale R., Toschi A., Aslan A. T., Massaro G., Maccaro A., Fabbricatore D., et al.

International Journal of Antimicrobial Agents , cilt.61, sa.3, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

39. Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study

Tabah A., Buetti N., Staiquly Q., Ruckly S., AKOVA M., ASLAN A. T., et al.

Intensive care medicine , cilt.49, sa.2, ss.178-190, 2023 (SCI-Expanded, Scopus)

40. Higher rates of cefiderocol resistance among NDM producing Klebsiella bloodstream isolates applying EUCAST over CLSI breakpoints

Isler B., Vatansever C., Özer B., ÇINAR G., ASLAN A. T., Falconer C., et al.

Infectious Diseases , cilt.55, sa.9, ss.607-613, 2023 (SCI-Expanded, Scopus)

41. Enhancing Public Health Communication Regarding Vaccine Trials: Design and Development of the Pan-European VACCELERATE Toolkit

Argyropoulos C. D., Leckler J., Salmanton-García J., Constantinou M., Alexandrou A., Themistocleous S., et al.

JMIR Public Health and Surveillance , cilt.9, 2023 (SCI-Expanded, SSCI, Scopus)

42. Knowledge and Attitudes of Turkish Physicians towards Human Monkeypox Disease and Related Vaccination: A Cross-Sectional Study

ŞAHİN T. K., ERUL E., AKSUN M. S., SÖNMEZER M. Ç., ÜNAL S., AKOVA M.

Vaccines , cilt.11, sa.1, 2023 (SCI-Expanded, Scopus)

43. Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia

Bergeron A., Mikulska M., De Greef J., Bondeelle L., Franquet T., Herrmann J., et al.

The Lancet Infectious Diseases , cilt.22, sa.12, 2022 (SCI-Expanded, Scopus)

44. Foreword

Pagliuca A., AKOVA M.

The Journal of antimicrobial chemotherapy , cilt.77, sa.2, 2022 (SCI-Expanded, Scopus)

45. Treatment strategies for OXA-48-like and NDM producing Klebsiella pneumoniae infections

Isler B., Aslan A. T., AKOVA M., Harris P., Paterson D. L.

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY , cilt.20, sa.11, ss.1389-1400, 2022 (SCI-Expanded, Scopus)

46. Pseudomonas aeruginosa Bloodstream Infections in Patients with Cancer: Differences between Patients with Hematological Malignancies and Solid Tumors

Royo-Cebrecos C., Laporte-Amargos J., Pena M., Ruiz-Camps I., Puerta-Alcalde P., Abdala E., et al.

PATHOGENS , cilt.11, sa.10, 2022 (SCI-Expanded, Scopus)

47. Relevance of the Consensus Principles for Appropriate Antibiotic Prescribing in 2022

Canton R., AKOVA M., Langfeld K., Torumkuney D.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY , cilt.77, ss.2-9, 2022 (SCI-Expanded, Scopus)

48. Comparison of ceftazidime-avibactam susceptibility testing methods against OXA-48-like carrying Klebsiella blood stream isolates

Isler B., Vatansever C., Ozer B., ÇINAR G., ASLAN A. T., Stewart A., et al.

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE , cilt.104, sa.1, 2022 (SCI-Expanded, Scopus)

49. Piperacillin-Tazobactam Plus Vancomycin-Associated Acute Kidney Injury in Adults: Can Teicoplanin or Other Antipseudomonal Beta-Lactams Be Remedies?

Aslan A. T., Akova M.

HEALTHCARE , cilt.10, sa.8, 2022 (SCI-Expanded, SSCI, Scopus)

50. VACCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolment

Salmanton-García J., Stewart F. A., Heringer S., Koniordou M., Álvarez-Barco E., Argyropoulos C. D., et al.

Vaccine , cilt.40, sa.31, ss.4090-4097, 2022 (SCI-Expanded, Scopus)

51. Relative Vaccine Effectiveness of the Third Dose of CoronaVac or BNT162b2 Following a Two-Dose CoronaVac Regimen: A Prospective Observational Cohort Study from an Adult Vaccine Center in Turkey

SÖNMEZER M. Ç., TELLİ DİZMAN G., Erul E., ŞAHİN T. K., SARICAOĞLU T., Alp A., et al.

VACCINES , cilt.10, sa.7, 2022 (SCI-Expanded, Scopus)

52. COVID-19 vaccine booster strategy: striving for best practice

DURUSU TANRIÖVER M., AKOVA M.

LANCET GLOBAL HEALTH , cilt.10, sa.6, 2022 (SCI-Expanded, SSCI, Scopus)

53. Is there still a room for improvement in antimicrobial use in a setting where use of broad-spectrum antibiotics require approval of an infectious diseases physician?

Metan G., UZUN Ö., Dizman G., SÖNMEZER M. Ç., İNKAYA A. Ç., HAZIROLAN G., et al.

Infection control and hospital epidemiology , cilt.43, sa.6, ss.802-804, 2022 (SCI-Expanded, Scopus)

54. Characteristics and outcomes of carbapenemase harbouring carbapenem-resistant Klebsiella spp. bloodstream infections: a multicentre prospective cohort study in an OXA-48 endemic setting

Isler B., Ozer B., ÇINAR G., ASLAN A. T., Vatansever C., Falconer C., et al.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES , cilt.41, sa.5, ss.841-847, 2022 (SCI-Expanded, Scopus)

55. Barriers Against Hepatitis B Vaccination in High-Risk Adults: A Cross-Sectional Study

ASLAN A. T., ŞAŞMAZER B., AYAR Y., Duran Z. C., AKOVA M.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.33, sa.5, ss.427-436, 2022 (SCI-Expanded, Scopus, TRDizin)

56. The ESCMID ethics advisory committee (EEAC): purpose and challenges Comment

Righi E., Yahav D., AKOVA M., Nasim A., Barac A.

CLINICAL MICROBIOLOGY AND INFECTION , cilt.28, sa.4, ss.470-471, 2022 (SCI-Expanded, Scopus)

57. Effect of Combination Antibiotic Empirical Therapy on Mortality in Neutropenic Cancer Patients with Pseudomonas aeruginosa Pneumonia

Albasanz-Puig A., Dura-Miralles X., Laporte-Amargos J., Mussetti A., Ruiz-Camps I., Puerta-Alcalde P., et al.

MICROORGANISMS , cilt.10, sa.4, 2022 (SCI-Expanded, Scopus)

58. A retrospective observational cohort study of the clinical epidemiology of bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae in an OXA-48 endemic setting.

Aslan A. T., Kırbaş E., Sancak B., Tanrıverdi E. S., Otlu B., Gürsoy N. C., et al.

International journal of antimicrobial agents , cilt.59, ss.106554, 2022 (SCI-Expanded, Scopus)

59. The Role of Colistin in the Era of New beta-Lactam/beta-Lactamase Inhibitor Combinations

Aslan A. T., AKOVA M.

ANTIBIOTICS-BASEL , cilt.11, sa.2, 2022 (SCI-Expanded, Scopus)

60. Voriconazole Therapeutic Drug Level Monitoring: A University Hospital Experience

KARA E., BAKIR EKİNCİ P., METAN G., EKİNCİOĞLU A., PINAR A., AKOVA M., et al.

FLORA INFEKSIYON HASTALIKLARI VE KLINIK MIKROBIYOLOJI DERGISI , cilt.27, sa.1, ss.183-188, 2022 (ESCI, TRDizin)

61. CoronaVac efficacy data from Turkey – Authors' reply

DURUSU TANRIÖVER M., Doğanay H. L., ÜNAL S., AKOVA M.

The Lancet , cilt.398, sa.10314, ss.1874, 2021 (SCI-Expanded, Scopus)

62. Untitled reply

Tanriover M. D., Doganay H. L., ÜNAL S., AKOVA M.

LANCET , cilt.398, sa.10314, ss.1874, 2021 (SCI-Expanded, Scopus)

63. Implementation of Pharmacist-Driven Antifungal Stewardship Program in a Tertiary Care Hospital

KARA E., METAN G., Bayraktar-Ekincioglu A., GÜLMEZ KIVANÇ D., ARIKAN AKDAĞLI S., DEMİRKAZIK F., et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY , cilt.65, sa.9, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

64. Comparison of teicoplanin versus vancomycin in combination with piperacillin-tazobactam or meropenem for the risk of acute kidney injury

ASLAN A. T., Pashayev T., DAĞ O., AKOVA M.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES , cilt.40, sa.9, ss.1953-1961, 2021 (SCI-Expanded, Scopus)

65. Etiology and prevalence of ESBLs in adult community-onset urinary tract infections in East China: A prospective multicenter study

Quan J., Dai H., Liao W., Zhao D., Shi Q., Zhang L., et al.

JOURNAL OF INFECTION , cilt.83, sa.2, ss.175-181, 2021 (SCI-Expanded, Scopus)

66. Expect the unexpected: fungemia caused by uncommon Candida species in a Turkish University Hospital

Özyavuz Alp Ş., Gülmez Kıvanç D., Kardaş R. C., Karahan G., Taş Z., Gürsoy G., et al.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES , cilt.40, sa.7, ss.1539-1545, 2021 (SCI-Expanded, Scopus)

67. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

DURUSU TANRIÖVER M., Doganay H. L., AKOVA M., Guner H. R., Azap A., AKHAN S., et al.

LANCET , cilt.398, sa.10296, ss.213-222, 2021 (SCI-Expanded, Scopus)

68. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial

AKOVA M., ÜNAL S.

TRIALS , cilt.22, sa.1, 2021 (SCI-Expanded, Scopus)

69. Persistent dermal lesions in a patient with previous history of visceral leishmaniasis

Jaiteh M. B., İNKAYA A. Ç., ÜNER A., ELÇİN G., ERGÜVEN S., KURTULAN O., et al.

PARASITOLOGY INTERNATIONAL , cilt.80, 2021 (SCI-Expanded, Scopus)

70. Pulmonary nocardiosis caused by Nocardia abscessus mimicking pulmonary thromboembolism in a patient with atypical anti-glomerular basement membrane glomerulonephritis

Ismayilov R., Koray N., İNAL N., TELLİ DİZMAN G., HAZIROLAN G., DURUSU TANRIÖVER M., et al.

TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX , cilt.69, sa.2, ss.237-241, 2021 (ESCI, Scopus, TRDizin)

71. Effects of Cytochrome p450 (CYP) 2C19 Genetic Polymorphisms on Voriconazole Serum Levels: A Report of Two Cases

TAŞ Z., KARA E., DEĞER O., İspirli M., METAN G., BABAOĞLU M. Ö., et al.

Mediterranean Journal of Infection, Microbes and Antimicrobials , cilt.10, 2021 (Scopus)

72. Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: the DIANA study

De Bus L., Depuydt P., Steen J., Dhaese S., De Smet K., Tabah A., et al.

INTENSIVE CARE MEDICINE , cilt.46, sa.7, ss.1404-1417, 2020 (SCI-Expanded, Scopus)

73. Fungal infections of the skin and soft tissue

DOĞAN GÜNAYDIN S., ARIKAN AKDAĞLI S., AKOVA M.

CURRENT OPINION IN INFECTIOUS DISEASES , cilt.33, sa.2, ss.130-136, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

74. Antimicrobial Stewardship in Hematological Patients at the intensive care unit: a global cross-sectional survey from the Nine-i Investigators Network

Rello J., Sarda C., Mokart D., Arvaniti K., AKOVA M., Tabah A., et al.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES , cilt.39, sa.2, ss.385-392, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

75. Understanding resistance in Pseudomonas

Dimopoulos G., AKOVA M., Rello J., Poulakou G.

INTENSIVE CARE MEDICINE , cilt.46, sa.2, ss.350-352, 2020 (SCI-Expanded, Scopus)

76. Splenic Actinomycosis in a Patient with Chronic Granulomatous Disease: A Case Report and Review of the Literature

AYAZ Ç. M., Hasanlı N., Demirci Duarte S., HAZIROLAN G., İNKAYA A. Ç., ÇİFTÇİ T. T., et al.

Infectious Diseases and Clinical Microbiology , cilt.1, sa.3, ss.158-164, 2019 (TRDizin)

77. Ultrastructural evaluation of urine alkalinization versus hydration on colistin-induced nephrotoxicity

Korucu B., Unal I., Pekcan M., İNKAYA A. Ç., Yeter H. H., ÇETİNKAYA M. A., et al.

Human and Experimental Toxicology , cilt.38, sa.12, ss.1366-1377, 2019 (SCI-Expanded, Scopus)

78. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium

Cornely O. A., Alastruey-Izquierdo A., Arenz D., Chen S. C. A., Dannaoui E., Hochhegger B., et al.

LANCET INFECTIOUS DISEASES , cilt.19, sa.12, 2019 (SCI-Expanded, Scopus)

79. Extended spectrum beta-lactamase producing enterobacteriaceae: carbapenem sparing options

ASLAN A. T., AKOVA M.

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY , 2019 (SCI-Expanded, Scopus)

80. Dual Role of gnaA in Antibiotic Resistance and Virulence in Acinetobacter baumannii

Xu Q., Chen T., Yan B., Zhang L., Pi B., Yang Y., et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY , cilt.63, sa.10, 2019 (SCI-Expanded, Scopus)

81. Impact of antibiotic resistance on outcomes of neutropenic cancer patients with Pseudomonas aeruginosa bacteraemia (IRONIC study): study protocol of a retrospective multicentre international study

Albasanz-Puig A., Gudiol C., Parody R., Tebe C., AKOVA M., Araos R., et al.

BMJ OPEN , cilt.9, sa.5, 2019 (SCI-Expanded, Scopus)

82. Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the FUNgal infections Definitions in ICU patients (FUNDICU) project

Bassetti M., Scudeller L., Giacobbe D. R., Lamoth F., Righi E., Zuccaro V., et al.

MYCOSES , cilt.62, sa.4, ss.310-319, 2019 (SCI-Expanded, Scopus)

83. Immigrants as donors and transplant recipients: specific considerations

Poulakou G., Len O., AKOVA M.

INTENSIVE CARE MEDICINE , cilt.45, sa.3, ss.401-403, 2019 (SCI-Expanded, Scopus)

84. Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing Escherichia coli and ESBL-Producing Klebsiella pneumoniae

Scheuerman O., Schechner V., Carmeli Y., Gutierrez-Gutierrez B., Calbo E., Almirante B., et al.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY , cilt.39, sa.6, ss.660-667, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

85. Neuroinvasive Listeriosis Could Petechial Hemorrhages be a Diagnostic Clue?

Diker S., OKAR S., Mehdikhanova L., ARSAVA E. M., KURNE A., CEVIK I. U., et al.

NEUROLOGIST , cilt.23, sa.3, ss.86-91, 2018 (SCI-Expanded, Scopus)

86. Acinetobacter baumannii Infection and Colonization in the Intensive Care Unit: Risk Factors, Transmission Routes, and Transmission Dynamics

KIZILARSLANOĞLU M. C., Ergonul O., Cetinkaya-Sardan Y., AKOVA M.

KLIMIK JOURNAL , cilt.31, sa.1, ss.20-29, 2018 (ESCI, Scopus, TRDizin)

87. Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance

De Waele J. J., AKOVA M., Antonelli M., Canton R., Carlet J., De Backer D., et al.

INTENSIVE CARE MEDICINE , cilt.44, sa.2, ss.189-196, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

88. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines

Mikulska M., Averbuch D., Tissot F., Cordonnier C., AKOVA M., Calandra T., et al.

JOURNAL OF INFECTION , cilt.76, sa.1, ss.20-37, 2018 (SCI-Expanded, Scopus)

89. Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study

Harris P. N. A., Pezzani M. D., Gutierrez-Gutierrez B., Viale P., Hsueh P., Ruiz-Garbajosa P., et al.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS , cilt.50, sa.5, ss.664-672, 2017 (SCI-Expanded, Scopus)

90. Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum beta-Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort

Raquel Palacios-Baena Z., Gutierrez-Gutierrez B., Calbo E., Almirante B., Viale P., Oliver A., et al.

CLINICAL INFECTIOUS DISEASES , cilt.65, sa.10, ss.1615-1623, 2017 (SCI-Expanded, Scopus)

91. Bacteremic and non-bacteremic pneumonia caused by Acinetobacter baumannii in ICUs of South China: A Clinical and Microbiological Study

Tan Y., Zhou K., Tang X., Kudinha T., Wang L., Guo Z., et al.

SCIENTIFIC REPORTS , cilt.7, 2017 (SCI-Expanded, Scopus)

92. Efficacy of beta-Lactam/beta-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-beta-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia

Gudiol C., Royo-Cebrecos C., Abdala E., AKOVA M., Alvarez R., Maestro-de la Calle G., et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY , cilt.61, sa.8, 2017 (SCI-Expanded, Scopus)

93. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study

Gutierrez-Gutierrez B., Salamanca E., de Cueto M., Hsueh P., Viale P., Ramon Pano-Pardo J., et al.

LANCET INFECTIOUS DISEASES , cilt.17, sa.7, ss.726-734, 2017 (SCI-Expanded, Scopus)

94. An overview on severe infections in Europe

Dimopoulos G., AKOVA M.

INTENSIVE CARE MEDICINE , cilt.43, sa.5, ss.686-689, 2017 (SCI-Expanded, Scopus)

95. MP246IN VIVO EVALUATION OF PROTECTIVE EFFECT OF HYDRATION WITH SODIUM CHLORIDE VERSUS URINE ALKALINISATION ON COLISTIN INDUCED NEPHROTOXICITY IN RATS

KORUCU B., ÜNAL ı., PEKCAN M., ÇETİNKAYA M. A., KAYMAZ F. F., İNKAYA A. Ç., et al.

Nephrology Dialysis Transplantation , cilt.32, ss.516-517, 2017 (SCI-Expanded, Scopus)

96. IN VIVO EVALUATION OF PROTECTIVE EFFECT OF HYDRATION WITH SODIUM CHLORIDE VERSUS URINE ALKALINISATION ON COLISTIN INDUCED NEPHROTOXICITY IN RATS

Korucu B., Unal I., Pekcan M., ÇETİNKAYA M. A., KAYMAZ F. F., İNKAYA A. Ç., et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION , cilt.32, 2017 (SCI-Expanded, Scopus)

97. Prevalence of mcr-1 in Escherichia coli and Klebsiella pneumoniae recovered from bloodstream infections in China: a multicentre longitudinal study

Quan J., Li X., Chen Y., Jiang Y., Zhou Z., Zhang H., et al.

LANCET INFECTIOUS DISEASES , cilt.17, sa.4, ss.400-410, 2017 (SCI-Expanded, Scopus)

98. Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extendedspectrum- beta-lactamase-producing Enterobacteriaceae

Raquel Palacios-Baena Z., Gutierrez-Gutierrez B., De Cueto M., Viale P., Venditti M., Hernandez-Torres A., et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY , cilt.72, sa.3, ss.906-913, 2017 (SCI-Expanded, Scopus)

99. Antibacterial Resistance in Patients with Hematopoietic Stem Cell Transplantation

Alp Ş., AKOVA M.

MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES , cilt.9, 2017 (SCI-Expanded, Scopus)

100. Community-acquired pneumonia in adults: Highlighting missed opportunities for vaccination

Blasi F., AKOVA M., Bonanni P., Dartois N., Sauty E., Webber C., et al.

EUROPEAN JOURNAL OF INTERNAL MEDICINE , cilt.37, ss.13-18, 2017 (SCI-Expanded, Scopus)

101. Antimicrobial Stewardship in Turkey

Ergonul O., Can F., AKOVA M.

ANTIMICROBIAL STEWARDSHIP , cilt.2, ss.331-333, 2017 (SCI-Expanded)

102. High prevalence of ESBL-producing Escherichia coli and Klebsiella pneumoniae in community-onset bloodstream infections in China

Quan J., Zhao D., Liu L., Chen Y., Zhou J., Jiang Y., et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY , cilt.72, sa.1, ss.273-280, 2017 (SCI-Expanded, Scopus)

103. Antimicrobial Stewardship in Hematology Patients

AKOVA M.

ANTIMICROBIAL STEWARDSHIP , cilt.2, ss.205-217, 2017 (SCI-Expanded)

104. Reducing the impact of carbapenem-resistant Enterobacteriaceae on vulnerable patient groups: what can be done?

METAN G., AKOVA M.

CURRENT OPINION IN INFECTIOUS DISEASES , cilt.29, sa.6, ss.555-560, 2016 (SCI-Expanded, Scopus)

105. Evaluation of PNA-FISH Method for Direct Identification of Candida Species in Blood Culture Samples and Its Potential Impact on Guidance of Antifungal Therapy

Dogan O., İNKAYA A. Ç., Gulmez D., UZUN Ö., AKOVA M., ARIKAN AKDAĞLI S.

MIKROBIYOLOJI BULTENI , cilt.50, sa.4, ss.580-589, 2016 (SCI-Expanded, Scopus, TRDizin)

106. A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae

Gutierrez-Gutierrez B., Salamanca E., de Cueto M., Hsueh P., Viale P., Ramon Pano-Pardo J., et al.

MAYO CLINIC PROCEEDINGS , cilt.91, sa.10, ss.1362-1371, 2016 (SCI-Expanded, Scopus)

107. Epidemiology of carbapenem-resistant Klebsiella pneumoniae colonization: a surveillance study at a Turkish university hospital from 2009 to 2013

Zarakolu P., Eser O. K., Aladag E., Al-Zahranı I. A., Day K. M., Atmaca O., et al.

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE , cilt.85, ss.466-470, 2016 (SCI-Expanded, Scopus)

108. A Multinational, Preregistered Cohort Study of beta-Lactam/beta-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-beta-Lactamase-Producing Enterobacteriaceae

Gutierrez-Gutierrez B., Perez-Galera S., Salamanca E., de Cueto M., Calbo E., Almirante B., et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY , cilt.60, sa.7, ss.4159-4169, 2016 (SCI-Expanded, Scopus)

109. Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study

Gutierrez-Gutierrez B., Bonomo R. A., Carmeli Y., Paterson D. L., Almirante B., Martinez-Martinez L., et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY , cilt.71, sa.6, ss.1672-1680, 2016 (SCI-Expanded, Scopus)

110. Epidemiology of antimicrobial resistance in bloodstream infections

AKOVA M.

VIRULENCE , cilt.7, sa.3, ss.252-266, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

111. Prospective Evaluation of Infection Episodes in Cancer Patients in a Tertiary Care Academic Center: Microbiological Features and Risk Factors for Mortality

ÇALIK BAŞARAN N., Karaagaoglu E., Hascelik G., DURUSU TANRIÖVER M., AKOVA M.

TURKISH JOURNAL OF HEMATOLOGY , cilt.33, sa.4, ss.311-319, 2016 (SCI-Expanded, Scopus, TRDizin)

112. Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort

Abdul-Aziz M. H., Lipman J., AKOVA M., Bassetti M., De Waele J. J., Dimopoulos G., et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY , cilt.71, sa.1, ss.196-207, 2016 (SCI-Expanded, Scopus)

113. Task force on management and prevention of Acinetobacter baumannii infections in the ICU

Garnacho-Montero J., Dimopoulos G., Poulakou G., AKOVA M., Miguel Cisneros J., De Waele J., et al.

INTENSIVE CARE MEDICINE , cilt.41, sa.12, ss.2057-2075, 2015 (SCI-Expanded, Scopus)

114. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease

Torres A., Blasi F., Dartois N., AKOVA M.

THORAX , cilt.70, sa.10, ss.984-989, 2015 (SCI-Expanded, Scopus)

115. Epidemiology of candidaemia in a tertiary care university hospital: 10-year experience with 381 candidaemia episodes between 2001 and 2010

Alp S., ARIKAN-AKDAGLI S., GULMEZ D., ASCIOGLU S., UZUN Ö., AKOVA M.

MYCOSES , cilt.58, sa.8, ss.498-505, 2015 (SCI-Expanded, Scopus)

116. Evaluation of a new chromogenic medium, chromID OXA-48, for recovery of carbapenemase-producing Enterobacteriaceae from patients at a university hospital in Turkey

Zarakolu P., Day K. M., SIDJABAT H. E., KAMOLVIT W., Lanyon C. V., Cummings S. P., et al.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES , cilt.34, sa.3, ss.519-525, 2015 (SCI-Expanded, Scopus)

117. Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study

Sinnollareddy M. G., Roberts J. A., Lipman J., AKOVA M., Bassetti M., De Waele J. J., et al.

CRITICAL CARE , cilt.19, 2015 (SCI-Expanded, Scopus)

118. Epidemiology and emerging resistance in bacterial bloodstream infections in patients with hematologic malignancies

Kara O., Zarakolu P., AŞÇIOĞLU HAYRAN S., ETGÜL S., Uz B., BÜYÜKAŞIK Y., et al.

INFECTIOUS DISEASES , cilt.47, sa.10, ss.686-693, 2015 (SCI-Expanded, Scopus)

119. Recommendations for Risk Categorization and Prophylaxis of Invasive Fungal Diseases in Hematological Malignancies: A Critical Review of Evidence and Expert Opinion (TEO-4)

Boga C., Bolaman Z., Cagirgan S., Karadogan I., ÖZCAN M. A., ÖZKALEMKAŞ F., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.32, sa.2, ss.100-117, 2015 (SCI-Expanded, Scopus, TRDizin)

120. Molecular characterization of NDM-1-producing Acinetobacter pittii isolated from Turkey in 2006

Roca I., MOSQUEDA N., ALTUN B., ESPİNAL P., AKOVA M., VİLA J.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY , cilt.69, sa.12, ss.3437-3438, 2014 (SCI-Expanded, Scopus)

121. Impact of Loading Doses on the Time to Adequate Predicted Beta-Lactam Concentrations in Prolonged and Continuous Infusion Dosing Schemes Reply

Roberts J. A., Paul S. K., AKOVA M., Bassetti M., De Waele J. J., Dimopoulos G., et al.

CLINICAL INFECTIOUS DISEASES , cilt.59, sa.6, ss.907-908, 2014 (SCI-Expanded, Scopus)

122. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients

Mikulska M., Viscoli C., Orasch C., Livermore D. M., Averbuch D., Cordonnier C., et al.

JOURNAL OF INFECTION , cilt.68, sa.4, ss.321-331, 2014 (SCI-Expanded, Scopus)

123. DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current beta-Lactam Antibiotic Doses Sufficient for Critically Ill Patients?

Roberts J. A., Paul S. K., AKOVA M., Bassetti M., De Waele J. J., Dimopoulos G., et al.

CLINICAL INFECTIOUS DISEASES , cilt.58, sa.8, ss.1072-1083, 2014 (SCI-Expanded, Scopus)

124. Clinical Experience of Colistin-Glycopeptide Combination in Critically Ill Patients Infected with Gram-Negative Bacteria

Petrosillo N., GIANNELLA M., ANTONELLI M., ANTONINI M., BARSIC B., BELANCIC L., et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY , cilt.58, sa.2, ss.851-858, 2014 (SCI-Expanded, Scopus)

125. The risk of pneumococcal disease in lung diseases and the importance of adult vaccination in the treatment of adult pneumococcal disease in lung diseases

SAYINER A., MİRİCİ A., ÇİLLİ A., Uzaslan E., AKOVA M., ÖZHAN M. H., et al.

TUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX , cilt.62, sa.2, ss.154-159, 2014 (ESCI, Scopus, TRDizin) Sürdürülebilir Kalkınma

126. Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study

Blot S., Koulenti D., AKOVA M., Bassetti M., De Waele J. J., Dimopoulos G., et al.

CRITICAL CARE , cilt.18, sa.3, 2014 (SCI-Expanded, Scopus)

127. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011)

Averbuch D., Cordonnier C., Livermore D. M., Mikulska M., Orasch C., Viscoli C., et al.

HAEMATOLOGICA , cilt.98, sa.12, ss.1836-1847, 2013 (SCI-Expanded, Scopus)

128. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia

Averbuch D., Orasch C., Cordonnier C., Livermore D. M., Mikulska M., Viscoli C., et al.

HAEMATOLOGICA , cilt.98, sa.12, ss.1826-1835, 2013 (SCI-Expanded, Scopus)

129. A multidisciplinary team approach to the management of patients with suspected or diagnosed invasive fungal disease

Ben-Ami R., Halaburda K., Klyasova G., Metan G., Torosian T., AKOVA M.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY , cilt.68, ss.25-33, 2013 (SCI-Expanded, Scopus)

130. Oral Antibiotics for Fever in Low-Risk Neutropenic Patients With Cancer: A Double-Blind, Randomized, Multicenter Trial Comparing Single Daily Moxifloxacin With Twice Daily Ciprofloxacin Plus Amoxicillin/Clavulanic Acid Combination Therapy-EORTC Infectious Diseases Group Trial XV

Kern W. V., Marchetti O., Drgona L., AKAN H., Aoun M., Akova M., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.31, sa.9, ss.1149-1156, 2013 (SCI-Expanded, Scopus)

131. Management of febrile neutropenia in the era of bacterial resistance

ÖZYAVUZ ALP Ş., AKOVA M.

THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE , cilt.1, sa.1, ss.37-43, 2013 (ESCI, Scopus)

132. Pneumonia Caused by Fusobacterium necrophorum Is Lemierre SyndromeStill Current

GÜLMEZ KIVANÇ D., ÖZYAVUZ ALP Ş., TOPELİ İSKİT A., AKOVA M., HASÇELİK A. G.

Mikrobiyoloji Bulteni , cilt.45, ss.729-734, 2011 (SCI-Expanded, Scopus, TRDizin)

133. Low-level laser therapy supported teeth extractions of two patients receiving IV zolendronate

Kan B., Altay M. A., Tasar F., AKOVA M.

LASERS IN MEDICAL SCIENCE , cilt.26, sa.5, ss.569-575, 2011 (SCI-Expanded, Scopus)

134. Comparative Evaluation of In Vitro Activities of Carbapenemes Against Gram-Negative Pathogens: Turkish Data of COMPACT Study

KORTEN V., Soyletir G., YALÇIN A. N., Ogunc D., Dokuzoguz B., Esener H., et al.

MIKROBIYOLOJI BULTENI , cilt.45, sa.2, ss.197-209, 2011 (SCI-Expanded, Scopus, TRDizin)

135. Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients

Pagano L., AKOVA M., Dimopoulos G., Herbrecht R., Drgona L., Blijlevens N.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY , cilt.66, 2011 (SCI-Expanded, Scopus)

136. A novel fungal pathogen under the spotlight - Acremonium spp. associated fungaemia in an immunocompetent host

PÜRNAK T., Beyazit Y., Sahin G. O., Shorbagi A., AKOVA M.

MYCOSES , cilt.54, sa.1, ss.78-80, 2011 (SCI-Expanded, Scopus)

137. The spectrum of diseases causing fever of unknown origin in Turkey: a multicenter study

Kucukardali Y., ÖNCÜL M. O., Cavuslu S., Danaci M., Calangu S., Erdem H., et al.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES , cilt.12, sa.1, ss.71-79, 2008 (SCI-Expanded, Scopus)

138. TİGESİKLİN

ÇALIK BAŞARAN N., AKOVA M.

ANKEM Dergisi , cilt.21, sa.2, ss.29-33, 2007 (TRDizin)

139. The frequency of PER-1 type extended spectrum beta-lactamases in nosocomial isolates-of Pseudomonas aeruginosa

ZARAKOLU P., METAN G., AYDİN N. G., ALTUN B., HASÇELİK A. G., AKOVA M.

MIKROBIYOLOJI BULTENI , cilt.41, sa.3, ss.363-367, 2007 (SCI-Expanded, Scopus, TRDizin)

140. Metallo-beta-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues

Cornaglia G., Akova M., Amicosante G., Canton R., Cauda R., Docquier J., et al.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS , cilt.29, sa.4, ss.380-388, 2007 (SCI-Expanded, Scopus)

141. Emerging problem pathogens: A review of resistance patterns over time

Akova M.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES , cilt.10, 2006 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

142. Clinical research in the lay press: Irresponsible journalism raises a huge dose of doubt

Anaissie E. J., Segal B. H., Graybill J. R., Arndt C., Perfect J. R., Kleinberg M., et al.

CLINICAL INFECTIOUS DISEASES , cilt.43, sa.8, ss.1031-1039, 2006 (SCI-Expanded, Scopus)

143. Infectious complications in patients with hematological malignancies consulted by the Infectious Diseases team: a retrospective cohort study (1997-2001)

Guven G., Uzun O., CAKIR B., Akova M., Unal S.

SUPPORTIVE CARE IN CANCER , cilt.14, sa.1, ss.52-55, 2006 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

144. Fungal Infections in Neutropenic Patients

AKOVA M.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS , cilt.26, 2005 (SCI-Expanded, Scopus)

145. Çeşitli Hastanelerde İzole Edilen Stafilokok Suşlarının Fusidik Asit ve Sık Kullanılan Diğer Antibiyotiklere Duyarlılıkları

ALTUN B., KOCAGÖZ A. S., HASÇELİK A. G., UZUN Ö., AKOVA M., ÜNAL S.

Türk Mikrobiyoloji Cemiyeti Dergisi , cilt.33, ss.8-11, 2003 (TRDizin)

146. In vitro activities of new quinolones against Brucella melitensis isolated in a tertiary-care hospital in Turkey

Kocagoz S., Akova M., Altun B., Gur D., Hascelik G.

CLINICAL MICROBIOLOGY AND INFECTION , cilt.8, sa.4, ss.240-242, 2002 (SCI-Expanded, Scopus)

147. Analysis of a mini-outbreak of methicillin-resistant Staphylococcus aureus in a surgical ward by using arbitrarily primed-polymerase chain reaction

CETINKAYA Y., KOCAGOZ S., HAYRAN M., Uzun O., Akova M., GURSU G., et al.

JOURNAL OF CHEMOTHERAPY , cilt.12, sa.2, ss.138-144, 2000 (SCI-Expanded, Scopus)

148. Comparison of E test to microdilution for determining in vitro activities of antibiotics against Brucella melitensis

GUR D., KOCAGOZ S., Akova M., Unal S.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY , cilt.43, sa.9, ss.2337, 1999 (SCI-Expanded, Scopus)

149. Primary cutaneous aspergillosis in human immunodeficiency virus-infected patients: Two cases and review

ARIKAN S., Uzun O., CETINKAYA Y., KOCAGOZ S., Akova M., Unal S.

CLINICAL INFECTIOUS DISEASES , cilt.27, sa.3, ss.641-643, 1998 (SCI-Expanded, Scopus)

150. Correlation of in vitro fluconazole susceptibility with clinical outcome for severely ill patients with oropharyngeal candidiasis

ARIKAN S., AKOVA M., HAYRAN M., OZDEMIR O., ERMAN M., GUR D., et al.

CLINICAL INFECTIOUS DISEASES , cilt.26, sa.4, ss.903-908, 1998 (SCI-Expanded, Scopus)

151. A randomized multicenter comparative study of cefepime and ceftazidime in combination with amikacin in the treatment of patients with fever and neutropenia

ERMAN M., Akan H., KORTEN V., Ferhanoǧlu B., UZUN Ö., ÜNAL S., et al.

Clinical Infectious Diseases , cilt.25, sa.2, ss.463, 1997 (SCI-Expanded, Scopus)

152. Comparison of Etest, microdilution and colorimetric dilution with reference broth macrodilution method for antifungal susceptibility testing of clinically significant Candida species isolated from immunocompromised patients

ARIKAN S., Gur D., AKOVA M.

MYCOSES , cilt.40, ss.291-296, 1997 (SCI-Expanded, Scopus)

153. Native valve endocarditis with persistent embolization due to Neisseria mucosa [4]

Tuncer S., HAYRAN K. M., Akan O., Gur D., AKOVA M., ÜNAL S.

Clinical Microbiology and Infection , cilt.3, sa.1, ss.137-139, 1997 (Scopus)

154. Treatment of enteric fever with pefloxacin for 7 days versus 5 days: A randomized clinical trial

Unal S., HAYRAN M., TUNCER S., GUR D., Uzun O., Akova M., et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY , cilt.40, sa.12, ss.2898-2900, 1996 (SCI-Expanded, Scopus)

155. Efficacy of sulbactam-ampicillin for the treatment of severe diabetic foot infections

Akova M., Ozcebe O. İ., Gullu I., Unal S., GUR D., AKALIN S., et al.

JOURNAL OF CHEMOTHERAPY , cilt.8, sa.4, ss.284-289, 1996 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

156. Efficacy of a three day course of azithromycin in the treatment of community acquired pneumococcal pneumonia Preliminary report

UZUN Ö., Hayran M., AKOVA M., Akalın E.

Journal of Chemotherapy , cilt.6, sa.1, ss.53-57, 1994 (Scopus)

157. QUINOLONES IN TREATMENT OF HUMAN BRUCELLOSIS - COMPARATIVE TRIAL OF OFLOXACIN-RIFAMPIN VERSUS DOXYCYCLINE-RIFAMPIN

AKOVA M., UZUN O., AKALIN H., HAYRAN M., UNAL S., GUR D.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY , cilt.37, sa.9, ss.1831-1834, 1993 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

158. OXA-11, AN EXTENDED-SPECTRUM VARIANT OF OXA-10 (PSE-2) BETA-LACTAMASE FROM PSEUDOMONAS-AERUGINOSA

HALL L., LIVERMORE D., GUR D., AKOVA M., AKALIN H.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY , sa.8, ss.1637-1644, 1993 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

159. Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole

AKOVA M., Akalin H., UZUN Ö., GÜR D.

European Journal of Clinical Microbiology & Infectious Diseases , cilt.10, sa.7, ss.598-599, 1991 (Scopus)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 23

1. EARLY CESSATION OF EMPIRICAL ANTIBACTERIAL THERAPY IN HIGH-RISK FEBRILE NEUTROPENIC PATIENTS WITH FEVER OF UNKNOWN ORIGIN (FUO)

KORUCU B., İNKAYA A. Ç., ERBİL A., OKAY M., AŞÇIOĞLU S., TOKUÇOĞLU ALTUNAY H., et al.

20TH SYMPOSIUM ON INFECTIONS IN THE IMMUNOCOMPROMISED HOST, ATİNA, Yunanistan, 17 - 19 Temmuz 2019, ss.76, (Özet Bildiri)

2. Mixed fungemia within 18-years in a university hospital and antifungal susceptibility profiles of the isolates

GÜLMEZ KIVANÇ D., ÖZYAVUZ ALP Ş., GÜRSOY G., AYAZ Ç. M., DOĞAN Ö., ARIKAN AKDAĞLI S., et al.

Balkan Fungus 2018 First Balkan Conference on Medical Mycology and Mycotoxicology, Temeşvar, Romanya, 13 - 15 Eylül 2018, cilt.26, ss.70-71, (Özet Bildiri)

3. Compliance to the guideline of diagnostic tests in febrile neutropenic patients at a Turkish university hospital’

ZARAKOLU KÖŞKER I. P., AKOVA M., BÜYÜKAŞIK Y., DURUSU TANRIÖVER M., DİZDAR Ö., METAN G., et al.

20th Symposium on Infections in the immunocompromised host, Atina, Yunanistan, 17 - 19 Haziran 2018, (Tam Metin Bildiri)

4. Impact of effective antibiptic therapy on mortality in patients with XDR Acinetobacter baumannii bloodstream infections

ZARAKOLU KÖŞKER I. P., AKOVA M., ESER Ö., Özdede M., METAN G.

20th Symposium on Infections in the immunocompromised host, Atina, Yunanistan, 17 - 19 Haziran 2018, (Tam Metin Bildiri)

5. Concomitant Herpes Simplex and Cytomegalovirus Reactivations in a Mycosis Fungoides Patient under Romidepsin Treatment: A Case Report

İNKAYA A. Ç., DOĞAN GÜNAYDIN S., ÖZYAVUZ ALP Ş., AKOVA M.

20th ICHS Symposium on Infections in the Immunocompromised Host, 17 - 19 Haziran 2018, (Özet Bildiri)

6. Evaluation of 2 commercial assays for the rapid confirmation of OXA-48 carbapenemases from Klebsiella pneumoniae isolates’, P3, p.72, Athens, Greece, 2018.

ZARAKOLU KÖŞKER I. P., AKOVA M., Perry J., ASLAN A. T.

20th Symposium on Infections in the immunocompromised host, Atina, Yunanistan, 17 - 19 Haziran 2018, (Tam Metin Bildiri)

7. SALMONELLA GRUP D’NİN NEDEN OLDUĞU SEPTİK ARTRİT OLGUSU

KARDAŞ R. C., BIÇAKCIGİL A., ERDUT A., ÇİÇEK M., LİSTE Ü., ALTUN B., et al.

4 ULUSAL KLİNİK MİKROBİYOLOJİ KONGRESİ, Türkiye, 8 - 12 Kasım 2017, (Özet Bildiri)

8. Fungemia due to rare yeasts and antifungal susceptibility profiles in a tertiary care university center

ÖZYAVUZ ALP Ş., GÜLMEZ KIVANÇ D., AYAZ Ç. M., ARIKAN AKDAĞLI S., AKOVA M.

8th Trends in Medical Mycology, 6 - 09 Ekim 2017, (Özet Bildiri)

9. In vivo evaluation of protective effect of hydration with sodium chloride versus urine

KORUCU B., ünal ı., PEKCAN M., ÇETİNKAYA M. A., KAYMAZ F. F., HAYRAN K. M., et al.

54th era-edta congress, 3 - 06 Haziran 2017, (Tam Metin Bildiri)

10. IN VIVO EVALUATION OF PROTECTIVE EFFECT OF HYDRATION WITH SODIUM CHLORIDE VERSUS URINE ALKALINISATION ON COLISTIN INDUCED NEPHROTOXICITY IN RATS

KORUCU B., ÜNAL I., PEKCAN M., ÇETİNKAYA M. A., KAYMAZ F. F., İNKAYA A. Ç., et al.

54th ERA-EDTA CONGRESS, Madrid, İspanya, 3 - 06 Haziran 2017, (Özet Bildiri)

11. Can urine alkalinisation be a treatment option on colistin induced nephrotoxicity: an ultrastructural and histochemical study on rats

KORUCU B., ÜNAL I., PEKCAN M., ÇETİNKAYA M. A., KAYMAZ F. F., HAYRAN K. M., et al.

15th International Congress of Histochemistry and Cytochemistry (ICHC 2017) in Antalya, 18 - 21 Mayıs 2017, (Özet Bildiri)

12. The changing epidemiology of candidaemia in a tertiary care university centre. P0959

ÖZYAVUZ ALP Ş., GÜLMEZ KIVANÇ D., ARIKAN AKDAĞLI S., AKOVA M.

27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Viyana, Avusturya, 22 - 25 Nisan 2017, (Özet Bildiri)

13. Listeria rhomboensefalit Farklı yüzler farklı tarzlar

AKOVA M., GÖÇMEN R., KARLI OĞUZ H. K., MUT AŞKUN M., TOPÇUOĞLU M. A., ÜNAL ÇEVİK I., et al.

52. Ulusal Nöroloji Kongresi, Türkiye, 25 Kasım - 01 Aralık 2016

14. Levofloksasin profilaksisi alan hematolojik kanserli nötropenik hastalarda kinolon dirençli Escherichia coli sürveyansı

ETGÜL S., ZARAKOLU KÖŞKER I. P., ESER Ö., KARA Ö., BÜYÜKAŞIK Y., Akova M.

3. Ulusal Klinik Mikrobiyoloji Uzmanlık Derneği Kongresi, Türkiye, 18 - 22 Kasım 2015, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

15. Etgül S P Zarakolu Ö K Eser Ö Kara Y Büyükaşık M Akova Impact of Levofloxacin Prophylaxis LP in Acute Leukaemia AL Patients with Neutropenia in a High Quinolone Resistance Setting Proc p P1207 Copenhagen Denmark 2015

ETGÜL S., ZARAKOLU KÖŞKER I. P., AKOVA M., Kara Ö.

24th European Congress of Clinical Microbiology and Infectious Diseases, 25 - 28 Nisan 2015, (Tam Metin Bildiri)

16. Kan kültürlerinden izole edilen Candida türlerinin PNA FISH yöntemiyle hızlı tanımlanmasının konvansiyonel tanımlama yöntemleriyle uyum ve antifungal tedavinin yönlendirilmesine olası etki yönünden değerlendirilmesi

DOĞAN AYÇIK Ö., İNKAYA A. Ç., GÜLMEZ KIVANÇ D., UZUN Ö., AKOVA M., ARIKAN AKDAĞLI S.

Febril Nötropeni Klavuz Toplantısı, Ankara, Türkiye, 29 - 30 Mart 2014, (Özet Bildiri)

17. Mart 2006 Ocak 2013 yılları arasında Hacettepe Üniversitesi Erişkin Hastanesi nde küf mantarı üremesi olan hastaların dağılımı

HA Y., ARIKAN AKDAĞLI S., GÜLMEZ KIVANÇ D., DOĞAN AYÇIK Ö., AKOVA M.

10. Febril Nötropeni Simpozyumu, Ankara, Türkiye, 17 - 19 Mayıs 2013, (Özet Bildiri) Sürdürülebilir Kalkınma

18. Epidemiology of Candida bloodstream infections and antifungal susceptibility profiles 10 year experience with 381 candidaemia episodes in a tertiary care university centre

ÖZYAVUZ ALP Ş., ARIKAN AKDAĞLI S., GÜLMEZ KIVANÇ D., AŞÇIOĞLU HAYRAN S., UZUN Ö., AKOVA M.

European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Londrina, Birleşik Krallık, 31 Mart - 03 Nisan 2012, (Özet Bildiri)

19. A retrospective study comparing cefoperazone sulbactam with piperacillin tazobactam as empirical therapy for febrile neutropenia in adults with hematological disorders

bitik b., ÖZYAVUZ ALP Ş., ÇALIK BAŞARAN N., AKOVA M., UZUN Ö., ÜNAL S.

8th Congress of The European Federation of Internal Medicine, İstanbul, Türkiye, 27 - 30 Mayıs 2009, cilt.20, ss.225, (Özet Bildiri)

20. HEMATOLOJİK MALİGNİTELİ HASTALARDA KAN DOLAŞIMI İNFEKSİYONLARININ SIKLIĞI VE ETKENLERİN DAĞILIMI HACETTEPE DE DEĞİŞİMİ

ÇALIK BAŞARAN N., ÖZVEREN A., AKOVA M.

8. FEBRİL NÖTROPENİ SEMPOZYUMU, Ankara, Türkiye, 21 - 24 Şubat 2008, (Özet Bildiri)

21. KANSER HASTALARINDA FUNGEMİ GÖRÜLME SIKLIĞI HACETTEPE DENEYİMİ

ÖZVEREN A., ÇALIK BAŞARAN N., AKOVA M.

8. FEBRİL NÖTROPENİ SEMPOZYUMU, Ankara, Türkiye, 21 - 24 Şubat 2008, ss.183, (Özet Bildiri)

22. EPIDEMIOLOGY OF BACTERIAL INFECTIONS AND RISK FACTORS FOR MORTALITY IN CANCER PATIENTS

ÇALIK BAŞARAN N., KARAAĞAOĞLU A. E., HASÇELİK A. G., AKOVA M.

INTERSCIENCE CONFERENCE ON ANTİMİCROBİAL AGENTS AND CHEMOTHERAPY, Washington, Kiribati, 16 - 19 Aralık 2005, (Özet Bildiri)

23. An open study of clarithromycin in the treatment of pneumonia due to Streptococcus pneumoniae

HAYRAN M., Erman M., GUR D., Akova M., Unal S.

3rd International Conference on the Macrolides, Azalides, and Streptogramins, Lisbon, Portekiz, 24 - 26 Ocak 1996, cilt.21, ss.429-431, (Tam Metin Bildiri)

Kitaplar 7

Metrikler

Yayın

198

Yayın (WoS)

156

Yayın (Scopus)

150

Atıf (WoS)

3500

H-İndeks (WoS)

Atıf (Scopus)

3810

H-İndeks (Scopus)

Atıf (Scholar)

H-İndeks (Scholar)

Atıf (Diğer Toplam)

Proje

Açık Erişim

BM Sürdürülebilir Kalkınma Amaçları

Yayınlar & Eserler